Phase I study of SYNB1891, an engineered E coli Nissle strain expressing STING agonist, with and without atezolizumab in advanced malignancies.

Jason J Luke,Sarina A Piha-Paul,Theresa Medina,Claire F Verschraegen,Mary Varterasian,Aoife M Brennan,Richard J Riese,Anna Sokolovska,James F Strauss,David L Hava,Filip Janku

Clinical cancer research : an official journal of the American Association for Cancer Research（2023）

引用 3|浏览20

暂无评分

摘要

Repeat IT injection of SYNB1891 as monotherapy and in combination atezolizumab was safe and well tolerated and evidence of STING pathway target engagement was observed.

查看译文

关键词

atezolizumab,nissle strain,synb1891,sting agonist

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要